Assembly Biosciences Company Insiders
| ASMB Stock | USD 13.33 0.41 3.17% |
About 84 percent of Assembly Biosciences' insiders are selling. The analysis of the overall insider sentiment regarding Assembly Biosciences suggests that quite a large number of insiders are terrified. Assembly Biosciences employs about 65 people. The company is managed by 32 executives with a total tenure of roughly 159 years, averaging almost 4.0 years of service per executive, having 2.03 employees per reported executive.
| John McHutchison CEO President CEO, Director |
| Derek Small CEO Co-Founder, CEO and President and Director |
Assembly Biosciences' Insider Buying Vs Selling
16
Selling | Buying |
Latest Trades
| 2024-04-01 | John G Mchutchison | Disposed 1206 @ 13.07 | View | ||
| 2024-03-27 | Jason A Okazaki | Disposed 392 @ 12.87 | View | ||
| 2024-01-17 | Alexander Schornstein | Acquired 24999 @ 9.36 | View | ||
| 2023-10-03 | Nicole S White | Disposed 157 @ 9.6 | View | ||
| 2023-07-24 | Jeanette M Bjorkquist | Disposed 70 @ 12.84 | View | ||
| 2023-05-23 | John G Mchutchison | Disposed 2164 @ 12.48 | View |
Monitoring Assembly Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Assembly |
Assembly Biosciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Assembly Biosciences' future performance. Based on our forecasts, it is anticipated that Assembly will maintain a workforce of about 70 employees by May 2024.Assembly Biosciences' latest congressional trading
Congressional trading in companies like Assembly Biosciences, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Assembly Biosciences by those in governmental positions are based on the same information available to the general public.
| 2021-01-04 | Representative Chris Jacobs | Disposed Under $15K | Verify |
Assembly Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.3387) % which means that it has lost $0.3387 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9895) %, meaning that it created substantial loss on money invested by shareholders. Assembly Biosciences' management efficiency ratios could be used to measure how well Assembly Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to -0.47. In addition to that, Return On Capital Employed is expected to decline to -0.69. At present, Assembly Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.07, whereas Total Assets are forecasted to decline to about 130.2 M.The current year's Common Stock Shares Outstanding is expected to grow to about 7.3 M, whereas Net Loss is forecasted to decline to (88 M).
Assembly Biosciences Workforce Comparison
Assembly Biosciences is rated fourth in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 624. Assembly Biosciences retains roughly 65.0 in number of employees claiming about 10% of equities under Health Care industry.
Assembly Biosciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Assembly Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Assembly Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Assembly Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 7.0 | 7 | 1 | 749,980 | 392.00 |
| 2023-12-01 | 1.0 | 6 | 6 | 932,500 | 6,622 |
| 2023-06-01 | 2.6 | 13 | 5 | 419,000 | 43,600 |
| 2023-03-01 | 1.4 | 7 | 5 | 653,250 | 28,018 |
| 2022-09-01 | 1.0 | 2 | 2 | 450,000 | 14,334 |
| 2022-06-01 | 11.0 | 11 | 1 | 220,000 | 4,164 |
| 2022-03-01 | 2.0 | 12 | 6 | 956,250 | 14,861 |
| 2021-09-01 | 2.0 | 2 | 1 | 40,938 | 12,156 |
| 2021-06-01 | 0.7778 | 7 | 9 | 120,000 | 145,629 |
| 2020-12-01 | 0.5 | 1 | 2 | 20,000 | 5,694 |
| 2020-03-01 | 2.5 | 10 | 4 | 720,383 | 11,066 |
| 2019-12-01 | 2.3333 | 7 | 3 | 430,061 | 67,582 |
| 2019-06-01 | 1.6 | 8 | 5 | 80,000 | 77,000 |
| 2018-09-01 | 1.0 | 4 | 4 | 28,400 | 17,540 |
| 2018-06-01 | 2.3333 | 14 | 6 | 170,413 | 6,000 |
| 2018-03-01 | 2.3333 | 14 | 6 | 444,250 | 6,000 |
| 2017-12-01 | 0.6667 | 4 | 6 | 23,000 | 6,000 |
| 2017-06-01 | 1.6 | 8 | 5 | 53,461 | 14,461 |
| 2016-06-01 | 8.0 | 8 | 1 | 110,263 | 0.00 |
| 2016-03-01 | 4.0 | 4 | 1 | 218,245 | 76,492 |
| 2015-12-01 | 1.0 | 1 | 1 | 30,000 | 0.00 |
| 2014-09-01 | 0.9259 | 25 | 27 | 5,607,533 | 2,304,583 |
| 2010-12-01 | 0.2 | 2 | 10 | 879,519 | 280,000 |
Assembly Biosciences Notable Stakeholders
An Assembly Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Assembly Biosciences often face trade-offs trying to please all of them. Assembly Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Assembly Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| John McHutchison | President CEO, Director | Profile | |
| Jason Okazaki | President CEO | Profile | |
| Derek Small | Co-Founder, CEO and President and Director | Profile | |
| William Ringo | Non-Executive Chairman of the Board | Profile | |
| Uri Lopatin | Vice President - Research & Development, Chief Medical Officer | Profile | |
| David Houck | Senior Vice President - Product Development and Portfolio Management | Profile | |
| Jacqueline Papkoff | Senior Vice President Chief Scientific Officer Microbiome | Profile | |
| Steven Knox | Senior Vice President - Clinical Development | Profile | |
| Graham Cooper | CFO, COO and Principal Financial Officer and Principal Accounting Officer | Profile | |
| David Barrett | CFO, COO | Profile | |
| Helen Kim | Independent Director | Profile | |
| Myron Holubiak | Independent Director | Profile | |
| Anthony Altig | Independent Director | Profile | |
| Susan Mahony | Director | Profile | |
| Richard DiMarchi | Director | Profile | |
| Mark Auerbach | Independent Director | Profile | |
| Alan Lewis | Director | Profile | |
| Nicole White | Chief Officer | Profile | |
| Adam Zlotnick | Chief CoFounder | Profile | |
| Richard Colonno | Chief Scientific Officer | Profile | |
| Thomas Rollins | Chief Development Officer | Profile | |
| Shannon Ryan | Corporate Relations | Profile | |
| Anuj MD | Chief Officer | Profile | |
| AO FRACP | CEO Director | Profile | |
| Uri MD | CoFounder Advisor | Profile | |
| Michele Anderson | Chief Officer | Profile | |
| Dr IV | Chief Officer | Profile | |
| Lee Arnold | Chief Scientific Officer | Profile | |
| Jeanette Bjorkquist | Executive Treasury | Profile | |
| Miguel Barbosa | Chief Scientific Officer, Head of Microbiome Program | Profile | |
| Tharaknath Rao | Head VP | Profile | |
| MHROD SHRMSCP | Chief Officer | Profile |
About Assembly Biosciences Management Performance
The success or failure of an entity such as Assembly Biosciences often depends on how effective the management is. Assembly Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Assembly management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Assembly management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.45) | (0.47) | |
| Return On Capital Employed | (0.66) | (0.69) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (1.49) | (1.42) |
The data published in Assembly Biosciences' official financial statements usually reflect Assembly Biosciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Assembly Biosciences. For example, before you start analyzing numbers published by Assembly accountants, it's critical to develop an understanding of what Assembly Biosciences' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Assembly Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Assembly Biosciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Assembly Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Assembly Biosciences. Please utilize our Beneish M Score to check the likelihood of Assembly Biosciences' management manipulating its earnings.
Assembly Biosciences Workforce Analysis
Traditionally, organizations such as Assembly Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Assembly Biosciences within its industry.Assembly Biosciences Manpower Efficiency
Return on Assembly Biosciences Manpower
| Revenue Per Employee | 110.2K | |
| Revenue Per Executive | 223.8K | |
| Net Loss Per Employee | 942K | |
| Net Loss Per Executive | 1.9M | |
| Working Capital Per Employee | 1.5M | |
| Working Capital Per Executive | 3M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Assembly Stock analysis
When running Assembly Biosciences' price analysis, check to measure Assembly Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assembly Biosciences is operating at the current time. Most of Assembly Biosciences' value examination focuses on studying past and present price action to predict the probability of Assembly Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assembly Biosciences' price. Additionally, you may evaluate how the addition of Assembly Biosciences to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stocks Directory Find actively traded stocks across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Assembly Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.38) | Revenue Per Share 1.565 | Quarterly Revenue Growth (1.00) | Return On Assets (0.34) | Return On Equity (0.99) |
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.